IGFBPL1 Antikörper (AA 201-278) (Biotin)

Produktnummer ABIN1701338

Produktdetails anti-IGFBPL1 Antikörper (Biotin)

Target: IGFBPL1 (Insulin-Like Growth Factor Binding Protein-Like 1 (IGFBPL1))

Bindungsspezifität: AA 201-278

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser IGFBPL1 Antikörper ist konjugiert mit Biotin

Applikation: ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Homologie: Human,Mouse,Rat,Dog,Cow,Sheep,Pig,Horse

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human IGFBPL1

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IHC-P 1:200-400
IHC-F 1:100-500

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C for 12 months.

Haltbarkeit: 12 months

Details zu IGFBPL1

Target: IGFBPL1 (Insulin-Like Growth Factor Binding Protein-Like 1 (IGFBPL1))

Andere Bezeichnung: IGFBPL1 (IGFBPL1 Produkte)

Synonyme: IGFBP-RP4 antikoerper, IGFBPRP4 antikoerper, bA113O24.1 antikoerper, 2810011G06Rik antikoerper, 2810453O06Rik antikoerper, IGFBPL antikoerper, insulin like growth factor binding protein like 1 antikoerper, insulin-like growth factor binding protein-like 1 antikoerper, IGFBPL1 antikoerper, Igfbpl1 antikoerper

Hintergrund:

Synonyms: bA113O24.1, IGFBP-related protein 10, IGFBP-RP4, IGFBPRP4, insulin-like growth factor binding protein related protein 4, insulin-like growth factor-binding protein-like 1, IBPL1_HUMAN, insulin-like growth factor-binding-related protein 4.

Background: IGFBPL1 is a secreted IGF (Insulin-like growth factor) binding protein that is known to contain an Ig-like C2-type (immunoglobulin-like) domain, an IGFBP N-terminal domain and a Kazal-like domain. IGF-binding proteins characteristically act to extend the half-life of IGFs and may influence the growth promoting effects of the IGFs. The interaction of IGFBPs with IGFs can affect cell surface receptors, specifically, IGFBPs may enhance or decrease a cells insulin sensitivity. IGFBPL1 has been found to be down-regulated in multiple tumors and thus may be a likely tumor suppressor candidate. Highly expressed in both brain and testis, IGFBPL1 is found at lower levels in the prostate, bladder and lung.